BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9488046)

  • 1. Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene.
    Greco A; Fusetti L; Miranda C; Villa R; Zanotti S; Pagliardini S; Pierotti MA
    Oncogene; 1998 Feb; 16(6):809-16. PubMed ID: 9488046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of TFG sequences outside the coiled-coil domain in TRK-T3 oncogenic activation.
    Roccato E; Pagliardini S; Cleris L; Canevari S; Formelli F; Pierotti MA; Greco A
    Oncogene; 2003 Feb; 22(6):807-18. PubMed ID: 12584559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain.
    Greco A; Mariani C; Miranda C; Lupas A; Pagliardini S; Pomati M; Pierotti MA
    Mol Cell Biol; 1995 Nov; 15(11):6118-27. PubMed ID: 7565764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic activation of the tyrosine kinase domain of the human trk proto-oncogene by fusion to a cell adhesion molecule.
    Albor A; Thraves PJ; Dritschilo A; Notario V
    Oncogene; 1996 Oct; 13(8):1755-63. PubMed ID: 8895522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes.
    Greco A; Miranda C; Pagliardini S; Fusetti L; Bongarzone I; Pierotti MA
    Genes Chromosomes Cancer; 1997 Jun; 19(2):112-23. PubMed ID: 9172002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xenopus laevis TRK-fused gene (TFG) is an SH3 domain binding protein highly expressed in the cement gland.
    Ohan N; Sabourin D; Booth RA; Liu XJ
    Mol Reprod Dev; 2000 Jul; 56(3):336-44. PubMed ID: 10861999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas.
    Butti MG; Bongarzone I; Ferraresi G; Mondellini P; Borrello MG; Pierotti MA
    Genomics; 1995 Jul; 28(1):15-24. PubMed ID: 7590742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium.
    Russell JP; Powell DJ; Cunnane M; Greco A; Portella G; Santoro M; Fusco A; Rothstein JL
    Oncogene; 2000 Nov; 19(50):5729-35. PubMed ID: 11126359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the NTRK1 genomic region involved in chromosomal rearrangements generating TRK oncogenes.
    Greco A; Mariani C; Miranda C; Pagliardini S; Pierotti MA
    Genomics; 1993 Nov; 18(2):397-400. PubMed ID: 8288244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas.
    Greco A; Pierotti MA; Bongarzone I; Pagliardini S; Lanzi C; Della Porta G
    Oncogene; 1992 Feb; 7(2):237-42. PubMed ID: 1532241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational analysis of conserved residues in the tyrosine kinase domain of the human trk oncogene.
    Mitra G
    Oncogene; 1991 Dec; 6(12):2237-41. PubMed ID: 1837350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of SHP-1-mediated down-regulation of the TRK-T3 oncoprotein identifies Trk-fused gene (TFG) as a novel SHP-1-interacting protein.
    Roccato E; Miranda C; Raho G; Pagliardini S; Pierotti MA; Greco A
    J Biol Chem; 2005 Feb; 280(5):3382-9. PubMed ID: 15557341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and functional domains critical for constitutive activation of the HGF-receptor (Met).
    Zhen Z; Giordano S; Longati P; Medico E; Campiglio M; Comoglio PM
    Oncogene; 1994 Jun; 9(6):1691-7. PubMed ID: 8183564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of TRK-T1 oncogene induces differentiation of PC12 cells.
    Greco A; Orlandi R; Mariani C; Miranda C; Borrello MG; Cattaneo A; Pagliardini S; Pierotti MA
    Cell Growth Differ; 1993 Jul; 4(7):539-46. PubMed ID: 8398895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neurotrophins. I: Molecular features].
    Zazpe A; Del Río J
    Rev Med Univ Navarra; 1997; 41(3):173-9. PubMed ID: 10420923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel modular mosaic of cell adhesion motifs in the extracellular domains of the neurogenic trk and trkB tyrosine kinase receptors.
    Schneider R; Schweiger M
    Oncogene; 1991 Oct; 6(10):1807-11. PubMed ID: 1656363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological activity of the thyroid TRK-T3 oncogene requires signalling through Shc.
    Roccato E; Miranda C; Ranzi V; Gishizki M; Pierotti MA; Greco A
    Br J Cancer; 2002 Sep; 87(6):645-53. PubMed ID: 12237775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor.
    Wiesmann C; Ultsch MH; Bass SH; de Vos AM
    Nature; 1999 Sep; 401(6749):184-8. PubMed ID: 10490030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.
    Wai DH; Knezevich SR; Lucas T; Jansen B; Kay RJ; Sorensen PH
    Oncogene; 2000 Feb; 19(7):906-15. PubMed ID: 10702799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The signaling adapters fibroblast growth factor receptor substrate 2 and 3 are activated by the thyroid TRK oncoproteins.
    Ranzi V; Meakin SO; Miranda C; Mondellini P; Pierotti MA; Greco A
    Endocrinology; 2003 Mar; 144(3):922-8. PubMed ID: 12586769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.